Business
ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets
BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA)
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":" BAUDETTE, Minn.--(BUSINESS WIRE)--\nANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg. The current annual U.S. market for this product is approximately $12.7 million, according to IQVIA/IMS Health.\n\n\"This is ANI’s seventh generic product launch in 2020 and reaffirms our commitment to increasing the pace of market introductions for our products. This important therapeutic is one of the pipeline generic products we acquired from Amerigen Pharmaceuticals, Ltd. earlier this year. I congratulate our team on this achievement and look forward to additional ANI product launches in the near future, as we focus on realizing the full potential of our product portfolio,” stated Nikhil Lalwani, President and CEO.\n\nAbout Aminocaproic Acid Tablets USP \n\nAminocaproic Acid Tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. For more information, including the complete list of indications and usages, please see the Full Prescribing Information.\n\nAbout ANI \n\nANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.\n\nForward-Looking Statements \n\nTo the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the development, manufacturing and commercialization of the product and any additional product launches from the generic pipeline acquired from Amerigen Pharmaceuticals, Ltd. and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “bel...